A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

计划入组 361 人 · 首次发布于 2025 年 6 月 19 日

The Switching Antiplatelet-9 (SWAP-9) Study

计划入组 90 人 · 首次发布于 2024 年 9 月 19 日

A Study of Nonoxynol-9 (N-9) and HIV Infection

计划入组 4,400 人 · 首次发布于 2001 年 8 月 31 日

PROTAC CDK2/9 Degrader-1(Sichuan University)

CDK2 (Plexium)

CDK1/CDK2 modulators (cancer)

宝鸡韩勇9+9制药厂

9 METERS BIOPHARMA, INC.

United States

ASSOCIACAO DE FORMANDOS DA 42 TURMA DA FACULDADE DE MEDICINA DO ABC-COMFOR XLII

Brazil

Cyclacel Completes Enrollment in Fadraciclib Trial for Tumors with CDKN2A/B Abnormalities

China Approves Xuanyuening (Bireociclib): First Dual-Indication CDK Inhibitor for Advanced Breast Cancer

Avenzo Therapeutics Initiates CDK4/CDK2 Dual Inhibitor Combination Trial for HR+/HER2- Breast Cancer